Indivior Pharmaceuticals, Inc. INDV

Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prompted fresh questions about valuation. See our latest analysis for Indivior Pharmaceuticals. At the current share price of $36.87, Indivior Pharmaceuticals has seen short term momentum fade, with a 1 month share price return that declined 8.85%, although the 1 year total shareholder return of...

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July’s sharp pullback.

• Q2’26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 • Record Quarterly Adjusted EBITDA of $186 Million in Q2'26, Up 111% YoY • Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reporte

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling greater financial flexibility to pursue internal and external growth opportunitiesCombined company expected to benefit from immediate scale and $125 million of expected annual cost synergiesCombined entity to be named Supernus, Inc. and Jack Khattar to serve as President and Chief